GT200000155A - Tratamiento de combinacion con il - 1ra y compuestos que inhiben el procesamiento y la liberacion il - 1. - Google Patents

Tratamiento de combinacion con il - 1ra y compuestos que inhiben el procesamiento y la liberacion il - 1.

Info

Publication number
GT200000155A
GT200000155A GT200000155A GT200000155A GT200000155A GT 200000155 A GT200000155 A GT 200000155A GT 200000155 A GT200000155 A GT 200000155A GT 200000155 A GT200000155 A GT 200000155A GT 200000155 A GT200000155 A GT 200000155A
Authority
GT
Guatemala
Prior art keywords
morby
compositions
methods
release
treatment
Prior art date
Application number
GT200000155A
Other languages
English (en)
Inventor
Bruce Henry Littman
Thasia Louise Goodwin Woodworth
Mark Anthony Dombroski
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200000155A publication Critical patent/GT200000155A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

EL INVENTO SE REFIERE A METODOS Y COMPOSICIONES PAR TRATAR Y PREVENIR ESTADOS MORBOSOS MEDIADOS POR LA IINTERLEUQUINA 1 ( IL 1RA ). EN LOS METODOS Y LAS COMPOSICIONES SE USA UN POLIPEPTIDO ANTAGONISTA DEL RECEPTOR DE LA INTERLEUCINA 1, O UNA VARIANTE DEL MISMO, EN COMBINACION CON UN AGENTE NO ESTEROIDE QUE INHIBE EL PROCESAMIENTO Y LA LIBERACION DE IL 1RA. AUNQUE LOS METODOS Y LAS COMPOSICIONES DEL PRESENTE INVENTO SON UTILES PARA EL TRATAMIENTO DE CUALQUIER ESTADO MORBOSO MEDIADO POR IL 1, EL ESTADO MORBOSO MEDIADO POR IL 1 ES PREFERIBLEMENTE SELECCIONADO DEL GRUPO QUE CONSISTE EN ENFERMEDADES CEREBRALES MEDIADAS POR CITOQUINAS, TALES COMO LA ENFERMEDAD DE ALZHEIMER; ENFERMEDADES INFLAMATORIAS TALES COMO INFLAMACIONES AGUDA Y CRONICA Y ARTRITIS REUMATOIDE; ENFERMEDADES DEGENERATIVAS DEL CARTILAGO Y OTRAS.
GT200000155A 1999-09-14 2000-09-14 Tratamiento de combinacion con il - 1ra y compuestos que inhiben el procesamiento y la liberacion il - 1. GT200000155A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15401099P 1999-09-14 1999-09-14

Publications (1)

Publication Number Publication Date
GT200000155A true GT200000155A (es) 2002-03-08

Family

ID=22549650

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200000155A GT200000155A (es) 1999-09-14 2000-09-14 Tratamiento de combinacion con il - 1ra y compuestos que inhiben el procesamiento y la liberacion il - 1.

Country Status (13)

Country Link
EP (1) EP1214087A1 (es)
JP (1) JP2003509378A (es)
AR (1) AR033650A1 (es)
AU (1) AU6464400A (es)
BR (1) BR0014003A (es)
CA (1) CA2383026A1 (es)
CO (1) CO5190701A1 (es)
EC (1) ECSP003652A (es)
GT (1) GT200000155A (es)
PA (1) PA8502901A1 (es)
PE (1) PE20010685A1 (es)
TN (1) TNSN00183A1 (es)
WO (1) WO2001019390A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2557910C (en) 2004-04-02 2012-05-29 Amgen Inc. Methods of reducing aggregation of il-1ra
WO2008129288A2 (en) * 2007-04-19 2008-10-30 Boehringer Ingelheim International Gmbh Disulfonamides useful in the treatment of inflammation
MD3259253T2 (ro) * 2015-02-16 2020-06-30 Univ Queensland Sulfoniluree și compuși înrudiți și utilizări ale acestora
JP2019512009A (ja) 2016-02-16 2019-05-09 ザ・ユニバーシティ・オブ・クイーンズランド スルホニルウレアおよび関連化合物ならびにこれらの利用
MA44729A (fr) * 2016-04-18 2021-05-12 Novartis Ag Composés et compositions pour traiter des états associés à une activité de nlrp
TW201837021A (zh) 2017-01-23 2018-10-16 美商傑庫爾醫療股份有限公司 作為介白素-1活性抑制劑之化合物
US11840543B2 (en) 2017-05-24 2023-12-12 The University Of Queensland Compounds and uses
EP3634951B8 (en) 2017-06-09 2024-08-21 Zydus Lifesciences Limited Novel substituted sulfoximine compounds
ES2906280T3 (es) 2017-07-07 2022-04-18 Inflazome Ltd Nuevos compuestos de sulfonamida carboxamida
US11370776B2 (en) 2017-07-07 2022-06-28 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
AU2018307743C1 (en) 2017-07-24 2021-09-09 Novartis Ag Compounds and compositions for treating conditions associated with NLRP activity
WO2019034693A1 (en) 2017-08-15 2019-02-21 Inflazome Limited SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3
AU2018317798A1 (en) * 2017-08-15 2020-02-13 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP
EP3668840A1 (en) 2017-08-15 2020-06-24 Inflazome Limited Novel sulfonamide carboxamide compounds
KR20200041337A (ko) 2017-08-15 2020-04-21 인플라좀 리미티드 신규한 설폰아마이드 카복스아마이드 화합물
UY37848A (es) 2017-08-15 2019-03-29 Inflazome Ltd Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3
WO2019043610A1 (en) 2017-08-31 2019-03-07 Cadila Healthcare Limited NEW SUBSTITUTED SULFONYLUREA DERIVATIVES
WO2019068772A1 (en) 2017-10-03 2019-04-11 Inflazome Limited NEW COMPOUNDS
EP3707134A1 (en) 2017-11-09 2020-09-16 Inflazome Limited Novel sulfonamide carboxamide compounds
WO2019166628A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
WO2019166627A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
EP3759090A1 (en) 2018-03-02 2021-01-06 Inflazome Limited Novel compounds
WO2019166619A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
US11530200B2 (en) 2018-03-02 2022-12-20 Inflazome Limited Compounds
GB201806578D0 (en) * 2018-04-23 2018-06-06 Inflazome Ltd Novel compound
EP3817817A1 (en) 2018-07-03 2021-05-12 Novartis AG Nlrp modulators
CA3104199A1 (en) 2018-07-20 2020-01-23 F. Hoffmann-La Roche Ag Sulfonylurea compounds as inhibitors of interleukin-1 activity
US20230011652A1 (en) 2018-10-24 2023-01-12 Novartis Ag Compounds and compositions for treating conditions associated with nlrp activity
US12084416B2 (en) 2019-01-14 2024-09-10 Zydus Lifesciences Limited Substituted sulfonylurea derivatives
CA3171969A1 (en) * 2020-05-25 2021-12-02 Beijing Vdjbio Co., Ltd. An interleukin-1 receptor antagonist and a fusion protein containing the same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874424A (en) * 1995-12-20 1999-02-23 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
TR199901816T2 (xx) * 1997-01-29 1999-11-22 Pfizer Inc S�lfonil �re t�revleri, bunlar�n interl�kin-1 aktivitesinin kontrol�nde kullan�mlar�.
US6015790A (en) * 1997-10-06 2000-01-18 Basf Aktiengesellschaft Methods and compositions for treating rheumatoid arthritis
EP0987552A3 (en) * 1998-08-31 2000-06-07 Pfizer Products Inc. Diarylsulfonylurea binding proteins

Also Published As

Publication number Publication date
BR0014003A (pt) 2002-05-21
CO5190701A1 (es) 2002-08-29
PA8502901A1 (es) 2002-02-21
TNSN00183A1 (fr) 2005-11-10
JP2003509378A (ja) 2003-03-11
PE20010685A1 (es) 2001-07-03
ECSP003652A (es) 2002-04-23
AU6464400A (en) 2001-04-17
EP1214087A1 (en) 2002-06-19
WO2001019390A1 (en) 2001-03-22
CA2383026A1 (en) 2001-03-22
AR033650A1 (es) 2004-01-07

Similar Documents

Publication Publication Date Title
GT200000155A (es) Tratamiento de combinacion con il - 1ra y compuestos que inhiben el procesamiento y la liberacion il - 1.
EP4310082A3 (en) Azolopyrimidine for the treatment of cancer-related disorders
ECSP066972A (es) Profármacos mutuos de glucosamina y glucosamina/anti-inflamatorio, composiciones, y métodos
ECSP034809A (es) Ciclobuteno-1,2-dionas 3,4-disustituidas como ligandos del receptor de quimocina cxc
CL2007001996A1 (es) Compuestos derivados de heteroarilos nitrogenados sustituidos con fenilo, inhibidores de la produccion de citoquinas; composicion farmaceutica que los comprende; y sus usos en el tratamiento del cancer, infecciones, enfermedades inflamatorias y autoinmunes.
UY38742A (es) Compuestos de 2,3,5-pyrazolo[1,5-a]pirimidina trisustituida
ES2192035T3 (es) Agentes anti-inflamatorios que presentan una selectividad para los glucocorticoides.
ECSP088752A (es) Formulaciones para administración parenteral de compuestos y sus usos
CL2004000849A1 (es) Compuestos derivados de benzamidas-2-hidroxi-3-diaminoalcanos, utiles para el tratamiento o la prevencion de alzheimer, sindrome de down, hemorragia cerebral hereditaria, demencias degenerativas y otras.
AR045900A1 (es) Compuesto glucocorticoesteroide, composiciones farmaceuticas que los contienen y su uso para el tratamiento de trastornos inflamatorios y/o alergicos.
CU23029A3 (es) Analogos sustituidos del benzopirano para el tratamiento de la inflamacion
ES2194567B1 (es) Imidazotriazinonas 2-fenil sustituidas como inhibidores de fosfodiesterasas.
NO20072235L (no) HCV-hemmende bicykliske pyrimidiner
GT200500007A (es) [1,8]naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia.
UY37813A (es) Derivados de pirrolopiridina sustituidos
CR9846A (es) 2-amino-7,8-dihidro-6h-pirido[4,3-d]pirimidina-5-onas
AR058561A1 (es) Control de la estabilidad de la forma de dosificacion de cci -779 a traves del control de impurezas de sustancias de farmaco
CL2003002043A1 (es) Compuestos derivados de tetrahidropiridina sustituidos en posicion 3 y 4; composicion farmaceutica, y sus usos en el tratamiento de enfermedades que estan asociadas con el sistema renina-angiotensina (ras), tales como hipertension, insuficiencia card
ECSP056006A (es) Composiciones farmacéuticas que comprenden una combinación de rapamicina o su derivado y pimecrolimus para el tratamiento de enfermedades inflamatorias e inmunológicamente mediadas
ES2058306T3 (es) Tetralinas substituidas, cromanos y compuestos relacionados en el tratamiento del asma, artritis y enfermedades relacionadas.
ECSP045277A (es) Composición oftálmica que comprende ascomicina
DK1032556T3 (da) Farmaceutisk aktive forbindelser og anvendelsesfremgangsmåder
AR117844A1 (es) Derivados de tiazolopiridina como antagonistas del receptor de adenosina
UY27413A1 (es) Agonistas de la oxitocina
DK0710239T3 (da) Nye 9-N-bicycliske nucleosidmidler anvendelige som selektive inhibitorer af proinflammatoriske cytokiner